Oncology

Latest News

Tech Updates: McKesson Launches Precision Oncology Consortium; Financing for RISA Labs PA Platform

By Mary Caffrey

April 17th 2025

These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.

Making Novel Cancer Therapies Available Requires Choices Because Resources Are Limited

By Kyle Munz

April 14th 2025

Businessman shows medical network wooden block for health, medicine, insurance, healthcare, care, concept. Medical technology services to solve public - ภัทรชัย รัตนชัยวงค์ - stock.adobe.com.jpeg

NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer

By Giuliana Grossi

April 9th 2025

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

By Galen Shearn-Nance, BS
Rishi R. Sachdev, BS

April 4th 2025

Woman with keloid on shoulder | Image credit: weerajata – stock.adobe.com

Deep Learning Tool Differentiates Keloids From Malignant Lesions Without Dermoscopy

By Hayden E. Klein

April 2nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

July 22nd 2014

Priority Review For Genentech's Avastin

July 22nd 2014

Truven Health Analytics' Tool to Improve Oncology Outcomes Research

July 21st 2014

HPV Screen Better Predictor of Cervical Cancer Risk Than Pap Test

The researchers found that the risk of developing cervical cancer within three years following a negative HPV test result was about half of the already low risk following a negative Pap test.

July 21st 2014

Breakthrough Therapy Designation for Aduro's Immunooncology Combination for Pancreatic Cancer

Aduro joins the exclusive group of companies, so far only the big pharma, that have a successful trail of immunooncology candidates.

July 17th 2014

In the Literature: No Survival Advantage Following Mastectomy in Stage I or II BRCA-Negative Breast Cancer

Preventive mastectomy did not improve survival in the study population.

July 16th 2014

Ira Klein, MD, MBA, FACP, Discusses Payer and ACO Oncology Care Pathways Participation

It is well known that oncology care pathways are the tools that practices can utilize to care for its patients. Ira Klein, MD, MBA, FACP, chief medical officer, National Accounts Clinical Sales & Strategy, Aetna, suggests that Aetna's only involvement in creating these pathways should be in helping these practices develop "reasonable care pathways."

July 16th 2014

Immunosignatures Could Replace Cancer Biomarkers in Early Diagnosis

The study, published in PNAS, showed that the peptide microarrays could classify complex heterogeneous cancers with upto 98% accuracy.

July 16th 2014

Study at Northwestern Medicine Proves Efficacy of Tamoxifen Gel in Breast Cancer

The study, published in Clinical Cancer Research, showed that the gel could prevent growth of breast cancer, with fewer side effects.

July 15th 2014

Literature: Method of Acquiring Tumor Samples Can Influence Proteomic Biomarkers

The authors sought to determine if tumor heterogeneity and biospecimen variables affect the evaluation of PI3K/Akt/mTOR pathway markers in breast cancer.

July 15th 2014

Alarming Results: Androgen-Deprivation in Early-Stage Prostate Cancer Patients May Not Influence Long-Term Survival

The long-term study, published in JAMA Internal Medicine, was conducted in more than 65,000 men over the age of 66 years with early-stage prostate cancer.

July 15th 2014

Genentech's Avastin Granted Priority Review: Cervical Cancer

Genentech submitted the BLA for bevacizumab for the treatment of recurrent or metastatic cervical cancer.

July 14th 2014

Encouraging Response to Roche's New MEK-Inhibitor in Melanoma Patients

Cobimetinib (MEK inhibitor), used in combination with Zelboraf (BRAF inhibitor), improved survival without disease progression.

July 14th 2014

Type of Anesthesia May Influence Breast Cancer Recurrence Post-Surgery

In vitro studies demonstrated a reduced incidence of apoptosis in patients administered inhaled anesthetics compared with those administered propofol during surgery.

July 14th 2014

In the Literature: PD-L1 Overexpression Associated With Activating EGFR Mutation in NSCLC

High expression of PD-L1 was associated with the presence of EGFR mutations in surgically resected NSCLC and was an independent negative prognostic factor for this disease.

July 11th 2014

Insurer's New Payment Model Saved Millions for Oncology Groups

Katie Sullivan, MA

One insurer's experimental reimbursement model proved to lower the total costs of care for patients with 3 types of cancer. As an alternative to the traditional fee-for-service payment model, the episode payment model-which reimburses physicians on a fixed-price, based on episodes of best-practices and patient outcomes-provided encouraging findings in the battle against the rising costs of cancer care in the United States.

July 10th 2014

In The Literature: Molecular Landscape of Lung Adenocarcinoma Published

Collaborative research conducted by scientists within the Cancer Genome Atlas Research Network have identified significant mutations that can influence tumor subtype classification.

July 10th 2014

BMS to Seek Approval for Nivolumab in the US to Treat Advanced Melanoma

Following approval in Japan, Nivolumab will be evaluated by the FDA for melanoma therapy in the US.

July 10th 2014

Cancer Patients Appreciate the Convenience of MyChart, Says Study

There has been a sharp increase in the number of cancer patients at one hospital using MyChart, the online, interactive service that allows patients to view laboratory and radiology results, communicate with their healthcare providers, and more.

July 9th 2014

UnitedHealthcare's Oncology Payment Model Shows Promise

UnitedHealthcare published these findings in the latest issue of Journal of Oncology Practice.

July 9th 2014

Pseudogenes: Novel Biomarkers For Identifying Tumor Subtypes?

The study by researchers at MD Anderson Cancer Center raises the possibility of using the information provided by these dysfunctional genes.

July 8th 2014

Eradicating Silos and Improving Communication in Cancer Care

Several cancer centers have programs in place to improve communication between PCPs and oncologists.

July 8th 2014

Biomarker-Directed, MS-Based Precision Surgery for Brain Cancer

A lipid metabolite, associated with more than 70 percent of brain cancers, can help distinguish and excise cancerous tissue.

July 7th 2014

Nivolumab (Opdivo) Approved in Japan for the Treatment of Advanced Melanoma

Nivolumab, the first PD-1 inhibitor, was approved in Japan for treating unresectable melanoma. It has been developed in Japan by Ono Pharmaceutical, which also has rights in Korea and Taiwan.

July 7th 2014

Trametinib Receives European Approval for B-Raf-mutant Metastatic Melanoma

GSK has received marketing authorization from the European Commission for trametinib as monotherapy for unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

July 7th 2014

What's in a Name — FDA Urged Not to Give Biosimilars Unique Names

This week, a coalition of 32 major pharmacies, health insurers, unions and pension plans asked the FDA not to require distinct names for biosimilar medications, arguing that such a move would not compromise patient safety, but could undermine the savings that are expected to be generated as these medicines are introduced into the US health care system.

July 7th 2014

In the Literature: Improved Chemotherapy Response Following Autophagy Inhibition in B-Raf-mutant Brain Tumors

Autophagy inhibition may improve cancer therapy, but it is unclear which tumors will benefit. BRAF mutations cause brain tumor cells to depend on autophagy and display selective chemosensitization with autophagy inhibition. We present a pediatric case in which deliberate autophagy inhibition halted tumor growth and overcame acquired BRAF-inhibition resistance.

July 3rd 2014

AJMC Panel Asks: Does It Pay to Use Pathways?

Clinical care pathways in oncology have gained notice with WellPoint's announcement of a $350 per patient, per month incentive. As WellPoint's effort starts this week, The American Journal of Managed Care convened a panel with the insurer's medical director for oncology care, ASCO President Peter Paul Yu, MD, and two other voices from the payer and provider realms to discuss how pathways are changing cancer care.

July 3rd 2014

Orteronel (TAK-700) Development Discontinued for Advanced Prostate Cancer

The lack of OS advantage is the reason for the discontinuation.

July 3rd 2014

FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma

July 2nd 2014

The Mammography Debate Resurfaces-This Time it's Medicare Spending

Despite increased spending, the breast cancer detection rate and stage did not change, according to a new JNCI study.

...

155 156 157 158 159 160 161 162 163

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions